RxDoctor Payments Data

Marion Davis, MD

Geriatric Medicine · Sumter, SCNPI 1760430573

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 36.3% of the total.

$1,632in general payments, 2019–2025

Across 94 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$593
  • Alkermes, Inc.$227
  • Neurocrine Biosciences, Inc.$211
  • AbbVie$138
  • Otsuka America Pharmaceutical, Inc.$133
  • Teva Pharmaceuticals USA, Inc.$106
  • plus $224 from 6 others

What the payments were for

  • Food & beverage$1,632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,632 in reported general payments places this provider in the 85th percentile of 41 geriatric medicine providers in South Carolina.

See all geriatric medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$17,806
Medicare patients
104
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate54$170,765
Risperdal ConstaRisperidone Microspheres22$37,732
VraylarCariprazine Hcl11$18,433
Aripiprazole337$17,069
Lurasidone Hcl54$10,564
Benztropine Mesylate444$8,500
Olanzapine301$5,836
Ziprasidone Hcl72$5,153
Divalproex Sodium ErDivalproex Sodium93$4,903
Haloperidol127$4,476
Clozapine50$3,137
Fluphenazine Hcl27$3,127
Paliperidone ErPaliperidone34$3,051
Oxcarbazepine19$2,652
Quetiapine Fumarate105$2,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$593$208,49776 claims
AbbVieVraylar$138$18,43311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 geriatric medicine providers in South Carolina.

Other geriatric medicine in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →